New Review Calls for Prioritizing Maternal Mental Health and SSRI Treatment During Pregnancy
核心洞察
A new JAMA Psychiatry review led by Children's National (搜索) urges a renewed focus on treating major depressive disorder (搜索) during pregnancy to protect maternal and infant health.
Approximately 12% of pregnant patients experience major depressive disorder (搜索), and 5% to 6% are treated with SSRIs, yet evidence shows untreated illness carries significant risks.
Accumulated evidence suggests SSRIs carry little or no risk for serious adverse outcomes once the effects of medication are separated from those of depression itself.
Treating depression during pregnancy is essential to protecting the health of mothers, babies and families, according to a new review led by Children's National (搜索) that calls for a renewed focus on maternal mental health and access to evidence-based care. The study, published in JAMA Psychiatry, examines the role of selective serotonin reuptake inhibitors (SSRIs) (搜索) and selective serotonin-norepinephrine inhibitors (SNRIs) (搜索) in treating major depressive disorder (搜索) during pregnancy.
Psychiatric conditions are a leading cause of maternal morbidity and mortality. The review emphasizes that major depressive disorder (搜索) is a complex brain disease shaped by genetic, environmental and epigenetic factors, and that untreated or undertreated illness can affect fetal and infant outcomes.
The Burden of Perinatal Mood Disorders
In the U.S., 5% to 6% of pregnant patients are treated with SSRIs, primarily for major depressive disorder (搜索), which affects about 12% of pregnant patients. The scope of the problem extends beyond depression alone: one in 5 individuals giving birth in the United States experiences a mood disorder during the perinatal period, defined as during pregnancy or up to 1 year postpartum. Anxiety is the most common condition (20.7%), followed by depression (12.1%).
The consequences of untreated illness are substantial. Untreated perinatal mood and anxiety disorders (搜索) create an environment of psychosocial toxicity that devolves into longitudinal adversity. The leading cause of death for mothers in the first year postpartum is untreated mental health disorders, outranking serious conditions like hemorrhage and hypertensive disease. Maternal depression in the postpartum year is also strongly associated with an increased unemployment risk for up to 15 years after childbirth, with an estimated societal cost of nearly $31,800 per affected mother-child dyad over the first 6 years.
Reframing the Risk-Benefit Discussion
"For too long, conversations about depression treatment during pregnancy have focused narrowly on medication exposure, rather than the very real risks of untreated illness," said Katherine Wisner, MD, MS, associate chief of Perinatal Mental Health at Children's National (搜索) and lead author of the study. "Our review reinforces that maternal mental health is central to the health of two generations. Patients deserve balanced, evidence-based guidance that helps them weigh the benefits of treatment alongside potential risks."
The review highlights several key findings. SSRIs are an essential component of perinatal mental health care for many patients with major depressive disorder (搜索). Evidence defining the benefits of SSRI treatment in pregnancy is more limited than evidence describing risks, but several studies show adverse effects when treatment is discontinued in patients with moderate to severe depression.
Evaluating SSRI safety during pregnancy is challenging because observational studies can be confounded by the underlying illness and related factors. However, when the effects of medication are separated from those of depression and its consequences, accumulated evidence suggests SSRIs carry little or no risk for serious adverse outcomes. The field is shifting toward prioritizing treatment of major depressive disorder (搜索) to optimize maternal health.
Safety Data in Context
Decades of quality, peer-reviewed research have demonstrated the favorable safety profile of SSRIs, the most commonly prescribed class of medications for depression and anxiety. Women with depression who are treated with SSRIs during pregnancy exhibit no clinically significant increased risk of miscarriage, fetal growth restriction, preterm birth, cesarean birth, or adverse neurodevelopmental outcomes compared with those with untreated depression. SSRIs are also widely considered compatible with breastfeeding because low amounts of these medications pass into breast milk.
Risks that do exist should be put into proper context. The baseline risk of birth defects in all pregnancies is about 3%. Exposure to an SSRI during pregnancy, including paroxetine, increases the risk of birth defects by less than 1%.
Treatment Discontinuation and Recurrence
More than half of women discontinue antidepressant medications during pregnancy. Yet, 53% of these women will end up back on antidepressants in the postpartum period, as the risk of symptom recurrence is 50% to 70% even in those who were euthymic at the time of discontinuation. Treatment decisions during pregnancy should therefore be framed as a risk-risk discussion, since lack of treatment is not neutral — untreated perinatal mood and anxiety disorders (搜索) themselves are associated with adverse obstetrical and neurodevelopmental outcomes.
Emerging Treatment Options
Timing is another consideration that significantly impacts a patient's quality of life. Traditional antidepressants like SSRIs must be used for 4 to 6 weeks at a therapeutic dose to yield significant clinical benefit. Today, postpartum patients have access to a new medication class that mimics the action of progesterone metabolites at the gamma-aminobutyric acid receptor. The rapid onset of these medications can produce reductions in depression scores within days. While more research is needed on which populations benefit most from traditional antidepressants versus novel ones, patients and clinicians alike now have more options to treat these serious mental health conditions.
A Call to Action
The authors call for coordinated improvements in clinical care and research, including expanded access to maternity, child health and psychiatric services, particularly in communities with limited care options. They also emphasize the importance of structured decision-making that considers the risks of untreated or undertreated illness, the benefits of treatment and the risks associated with SSRI exposure.
Currently, perinatal mood and anxiety disorders (搜索) remain untreated in 3 of 4 affected individuals giving birth, and the discrepancy between needing care and receiving care is highest in the most vulnerable populations: the marginalized, the socioeconomically disadvantaged, the isolated and the inadequately insured. It is imperative that obstetricians and primary care clinicians achieve basic competency in managing psychiatric disorders during the perinatal period.